Mithra Pharmaceuticals S.A.

Board/Management Information • Jun 20, 2022

Mithra Announces the Resignation of François Fornieri As Non-Executive Director

Liege, Belgium, 20 June 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces that Mr. François Fornieri resigned from his non-executive director mandate of the Company. Mr. Fornieri 's decision, founder and major shareholder of the Company, is based on personal reasons.

François Fornieri, founder and major shareholder of Mithra, commented: "At the end of this transitional year within the new Board of Directors in place since May 2021, I have decided, not without some emotion, to resign from my role as director. As a major shareholder, I restated my full confidence in the management team in place during the latest Shareholder's Meeting, as well as in the directors, all of whom were appointed by large majorities. Over the past year, I closely worked with the CEO and the Directors in order to transfer all my knowledge of this company which I managed for 22 years. I strongly believe that they have all the necessary expertise to lead the Company in its next strategic phases, in particular the conclusion of a commercial partnership agreement for Donesta® in the coming months. It is now time for me to dedicate my energy and expertise as an entrepreneur to other professional projects. As Mithra's founder and major shareholder, I will obviously continue to monitor closely its achievements and promising projects. Thanks to the strong intellectual property we have built around estetrol, I am confident that new developments will bring Mithra at the place it deserves in the biotech world."

Ajit Shetty, Chairman of Mithra's Board of Directors, commented: "On behalf of the Board of Directors, I would like to warmly thank Mr. Fornieri for his full commitment in this company which he created and developed during more than twenty years. It is thanks to his vision and determination to transform women's health that Mithra could start writing its own story. It is also thanks to his tenacity and will to lead Mithra to concretize its full potential that it allows us today, after an excellent transfer of competences, to continue our mission as directors and to lead Mithra successfully towards its next phase of development."

Following the resignation with immediate effect of Mr. Fornieri, Mithra's Board of Directors is now composed of 9 directors, including 5 women directors and 4 men directors, 5 independent and 4 nonindependent directors. These directors were appointed in May 2021 for a two-year term.

********

For more information, please contact:

Benoît Mathieu (IRO) : +32 473 35 80 18 - investorrelations@mithra.com Maud Vanderthommen (Press) : +32 473 58 61 04 – press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle® , Mithra is now focusing on its second product Donesta® , the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormonedependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium. www.mithra.com

Donesta® is a registered trademark of Mithra Pharmaceuticals or one of its affiliates.

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

News Alerts

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media : Linkedin • Twitter • Facebook